A giant leap in the Chinese market .. The shares of pharmaceutical and technology companies fly by 20%

The pharmaceutical and technology companies in the Chinese market have witnessed a strong rise today, as the gains topped both Staidson Beijing Biopharma, Dizal Jiangsu Pharmaceutical and Fujian Wanchen Biotechnology at heights that reached a daily limit (+20%), which reflects strong confidence from investors in this vital sector.

Pharmaceutical companies

Staidson Beijing Biopharma increased by +20.04% to 10.90 yuan, after gains of +1.82, and the company specializing in developing rare diseases and viruses, may have benefited from new news or developments in its production lines or organizational approvals.

Dizal Jiangsu Pharmaceutical also recorded a strong leap, as the stock rose by +9.80 yuan to 58.80 yuan, and the company is known for its advanced technologies in tumor treatments, and the height may be driven by announcing positive clinical results or strategic alliances.

As for Fujian Wanchen Biotechnology Co, its arrow rose to 135.48 yuan, gains of +22.58 yuan (20%), and there is likely to be a great momentum on biotechnology shares in light of the growing global interest in scientific research and fine medicines.

The health and pharmaceutical sector in China is going through a noticeable recovery stage, supported by technical developments, as well as possible government incentives for drug innovation and scientific research.

Technology companies

The gains were not limited to the pharmaceutical sector only, but also included technology and information companies, which reflects a positive general performance of innovation shares.

Henan Shijia Photons Technology its share jumped by 20% to 18.72 yuan, an increase of +3.12 yuan, and the company works in the field of photon and light technologies, a promising field, especially with the entry of artificial intelligence technologies and communications infrastructure expansion.

Hengfing Information increased by +20.03% to 17.32 yuan, after the gains +2.89 yuan. The company is working in providing digital information solutions, and has benefited from market transformations towards digitization and smart transformation.

The rise in technology shares also reflects the global trend of investment in innovation, as well as Chinese internal stimulus to develop digital structure as part of the “Smart China” strategy.

Reasons for future rise and expectations

The achievement of these companies for the gains of their daily maximum limits (20%) is not a random matter, but rather reflects strong indicators in terms of investment momentum and market optimism, and among the possible reasons:

Positive news or strong financial results: Some companies may have announced higher quarterly profits than expectations or financial data that support their future growth.

Entering institutional investors or large funds enter these shares, generating collective purchase waves.

Direct or indirect government incentives: such as supporting innovation, granting new drug licenses, or expanding plans in the biotechnology sector.

Technical analysis: These shares may have achieved technical price breakthroughs that attracted traders, especially if they are among previous resistance levels.

The future expectations of these shares remain positive, provided that the current momentum is continuing and supportive news, but it is necessary to note that strong heights are often followed by profit harvesting waves, so it is preferable for investors cautious, monitoring technical indicators and trading volume.